Emcure Pharmaceuticals share price
NSE: EMCUREBSE: 544210Pharmaceuticals & BiotechnologySmall Cap
Emcure Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2024 · Issue price ₹1,008
Last close ₹1,871.80up ₹6.80 (0.36%)BSE ₹1,868.10
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,865.00.
30 Oct: open ₹1,858.10, high ₹1,887.00, low ₹1,852.60
52-week range of traded prices to 30 Oct 2026
₹1,306.50Low, 4 Nov 2025₹2,100.70High, 18 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹35,510 Cr266th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 35.11
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 7.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.19%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 21.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 25.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 82,63359.5% delivered
About Emcure Pharmaceuticals
Emcure Pharmaceuticals is a Pune-based pharmaceutical company that develops, manufactures and markets medicines in India and abroad, with its core strength in formulations (finished medicines such as tablets) and a complementary presence in active pharmaceutical ingredients and contract research and manufacturing.1 It sells to patients through distributors and retailers, supplies institutional buyers such as government bodies, and exports through its subsidiaries and distributors to Europe, Canada and emerging markets.21
The group reports one operating segment, pharmaceuticals, and its products reach more than 80 countries.34 Its main brands in India include Orofer, Zostum, Bevon, Maxtra, Metpure and Tenectase.5 It also markets partners' brands in India: Novo Nordisk's Poviztra (semaglutide for chronic weight management), Sanofi's Amaryl and Cetapin, and select Roche nephrology and transplant products under an agreement signed in March 2026.67 Its material subsidiaries are Zuventus Healthcare in India and Tillomed Laboratories in Europe, and it sells in Canada through Marcan Pharmaceuticals and Mantra Pharma.869
Emcure was incorporated in April 1981, turned to branded generics in India in 1995, acquired Tillomed in the UK in 2014, entered Canada through the Marcan acquisition in 2015 and demerged its US business in 2020.11011 Its shares were listed on the NSE and BSE on 10 July 2024, and Zuventus became a wholly owned subsidiary on 3 October 2025.118
Founder Satish Mehta, who has led Emcure since 1981, is its Chairman, Managing Director and CEO; he and whole-time directors Sunil Mehta, Namita Thapar and Samit Mehta are its promoters.1213
Emcure Pharmaceuticals key points
Results
- In the year to Mar 2026, consolidated revenue from operations rose 16.6% to ₹92,035 million, crossing $1 billion; EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹17,886 million, its margin up 80 basis points (hundredths of a percentage point) to 19.4%.141516
- Reported net profit for the year to Mar 2026 was ₹9,413 million, a 10.2% margin; the company's adjusted net profit (excluding one-off items) was ₹10,075 million, up 41%. Return on capital employed (profit on the money invested in the business) was 23.7%.1718
- In the quarter to Jun 2026, revenue from operations rose 22.8% to ₹2,580 crore, EBITDA rose 25.8% to ₹508 crore at a 19.7% margin, and profit after tax rose 36.2% to ₹292 crore.1920
Market position
- In India, Emcure ranks 13th by market share and 2nd in gynaecology, with an 8.3% share there, and 19 of its top 20 brands rank among the top 3 in their therapy areas, as of the year to Mar 2026.2122
- Emcure ranks 1st in HIV antivirals in India, with a 45.5% share.23
- In Canada, Emcure is among the top 10 generic drug companies and is the largest Indian company by prescriptions.24
Where revenue comes from
- Share of revenue by region2526In the year to Mar 2026, India revenue grew 10% and international revenue 22.2%: Europe 25.5%, Canada 18.7% and the rest of the world 21.8%.
Item year to Mar 2026 India 44% Europe 20% Canada 16% Rest of World 20% - In the quarter to Jun 2026, India revenue rose 10.2% to ₹1,095 crore and international revenue 34.2% to ₹1,485 crore: Europe 32.8% to ₹537 crore, Canada 24.6% to ₹427 crore and the rest of the world 44.8% to ₹522 crore.2728
- The Europe business rests on complex injectables and specialty generics, sold directly in select markets such as the UK and Italy and through partners across the rest of the region; the Canada business sells through hospital, retail and over-the-counter (non-prescription) channels.2930
Plants and capacity
- Emcure has 13 manufacturing facilities in India, making oral medicines, injectables, active pharmaceutical ingredients (the active substances in medicines), peptides and biological products.31
- On 8 Aug 2026, the company said the US FDA had closed its May 2026 inspection of the Sanand, Gujarat formulations plant as Voluntary Action Indicated (objectionable conditions found, but no regulatory action planned).32
Research and development
- R&D spending was ₹3,835 million in the year to Mar 2026, 4.2% of revenue; the company has 5 R&D facilities, 548 scientists including 48 PhDs, and 220 patents.3334
- Emcure became the first generic company approved in the European Union for Liposomal Amphotericin B, an antifungal injection whose innovator (original brand) sales market the company puts at about $270 million.35
- Emcure holds Gilead's voluntary licence for the HIV drug lenacapavir; on its earnings call of 6 Aug 2026 it said it had signed in July a royalty-free licence from Merck Sharp & Dohme for an experimental monthly oral HIV pill in 129 lower-income countries.3637
What the company expects
- On its earnings call of 6 Aug 2026, the company said it expects low to mid-teen revenue growth in the year to Mar 2027 and is more comfortable at the higher end of that range.3839
- The company stated in its annual report for the year to Mar 2026 that it expects R&D investment to remain at 4% to 5% of revenue; on its earnings call of 6 Aug 2026, it kept that range for the year to Mar 2027.4041
- On its earnings call of 6 Aug 2026, the company said it should probably be net cash by Mar 2028, and expected net debt (borrowings less cash), ₹1,103 crore in June 2026, to rise after July payouts for Mantra and Gennova.4243
Recent events
- Emcure bought the remaining 12.05% of its biotech subsidiary Gennova Biopharmaceuticals for ₹2,318.7 million, making it wholly owned; the shares were credited on 21 Jul 2026.44
- On 20 Jul 2026, Emcure said Poviztra is available in India for MASH (a fatty liver disease with inflammation) in adults with moderate to advanced liver scarring, after the drug regulator approved the indication.45
- On 10 Jul 2026, Gennova agreed to sell its mRNA business to Immunoscript Life Science for ₹1,395 million in cash.4647
- On 1 Apr 2026, Mantra Pharma, part of the Canada business, bought Cutimed, adding dermatology products, and merged it into itself the same day.4849
Litigation and regulatory matters
- In its exchange filing of 2 Oct 2026, the company said Income-tax Department orders impose an aggregate penalty of ₹57,73,96,732 for the years to Mar 2015 through Mar 2021; it is evaluating legal remedies, including an appeal.50
Last updated
All 50 sources, each with its page
- 1. Annual report, 28 Aug 2026, page 82
- 2. Annual report, 28 Aug 2026, page 139
- 3. Annual report, 28 Aug 2026, page 336
- 4. Annual report, 28 Aug 2026, page 21
- 5. Annual report, 28 Aug 2026, page 32
- 6. Annual report, 28 Aug 2026, page 83
- 7. Annual report, 28 Aug 2026, page 14
- 8. Annual report, 28 Aug 2026, page 90
- 9. Annual report, 28 Aug 2026, page 43
- 10. Annual report, 28 Aug 2026, page 23
- 11. Annual report, 28 Aug 2026, page 24
- 12. Investor presentation, 25 Sep 2026, page 36
- 13. Annual report, 28 Aug 2026, page 106
- 14. Annual report, 28 Aug 2026, page 14
- 15. Annual report, 28 Aug 2026, page 26
- 16. Annual report, 28 Aug 2026, page 17
- 17. Annual report, 28 Aug 2026, page 17
- 18. Annual report, 28 Aug 2026, page 26
- 19. Earnings call, 6 Aug 2026, page 5
- 20. Earnings call, 6 Aug 2026, page 9
- 21. Annual report, 28 Aug 2026, page 83
- 22. Investor presentation, 25 Sep 2026, page 15
- 23. Annual report, 28 Aug 2026, page 30
- 24. Annual report, 28 Aug 2026, page 44
- 25. Annual report, 28 Aug 2026, page 22
- 26. Annual report, 28 Aug 2026, page 17
- 27. Earnings call, 6 Aug 2026, page 5
- 28. Earnings call, 6 Aug 2026, page 6
- 29. Annual report, 28 Aug 2026, page 41
- 30. Annual report, 28 Aug 2026, page 43
- 31. Annual report, 28 Aug 2026, page 25
- 32. Exchange filing, 8 Aug 2026, page 1
- 33. Annual report, 28 Aug 2026, page 19
- 34. Annual report, 28 Aug 2026, page 25
- 35. Annual report, 28 Aug 2026, page 41
- 36. Annual report, 28 Aug 2026, page 50
- 37. Earnings call, 6 Aug 2026, page 7
- 38. Earnings call, 6 Aug 2026, page 8
- 39. Earnings call, 6 Aug 2026, page 14
- 40. Annual report, 28 Aug 2026, page 19
- 41. Earnings call, 6 Aug 2026, page 16
- 42. Earnings call, 6 Aug 2026, page 15
- 43. Earnings call, 6 Aug 2026, page 9
- 44. Exchange filing, 22 Jul 2026, page 1
- 45. Exchange filing, 20 Jul 2026, page 2
- 46. Exchange filing, 11 Jul 2026, page 1
- 47. Exchange filing, 11 Jul 2026, page 2
- 48. Annual report, 28 Aug 2026, page 90
- 49. Annual report, 28 Aug 2026, page 43
- 50. Exchange filing, 2 Oct 2026, page 1
Results
Consolidated; ₹ crore.Emcure Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +18.4%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +35.9%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,580 Crup 4.48%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹292 Crup 20.00%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 11.3%
Revenue by quarter
Peak revenue ₹2,580 Cr, quarter to Jun 2026; lowest ₹1,963 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 |
| Net profit | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 |
| Net margin | 10.1% | 8.0% | 9.3% | 10.2% | 11.1% | 9.8% | 9.9% | 11.3% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹9,204 Crup 16.56%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹941 Crup 33.05%
- Net margin
- 10.2%
Revenue by year
Peak revenue ₹9,204 Cr, year to Mar 2026; lowest ₹7,896 Cr, year to Mar 2025
Net profit by year, a loss in red
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 7,896 | 9,204 |
| Net profit | 707 | 941 |
| Net margin | 9.0% | 10.2% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Emcure Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 54% of 247 trading days over the last year.
LowestHighest
Its median34.98Industry median27.53
Price to book
At or below today's level on 81% of 247 trading days over the last year.
LowestHighest
Its median6.51Industry median2.88
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 71% of 558 trading days since Jul 2024.
LowestHighest
Its median0.15%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +49.0% | +33.9% | +11.1% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
74 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 44 of the 51 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 74 funds holding Emcure Pharmaceuticals
- AddedAdded. Funds that held more shares than at the end of the month before.
- 46
- CutCut. Funds that held fewer shares than at the end of the month before.
- 5
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 22
| Fund | |||
|---|---|---|---|
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 43,15,000 | 1.26% | ₹838.4 Cr |
 Nippon India Multi Cap FundNippon India Mutual Fund | 15,47,263 | 0.56% | ₹300.6 Cr |
 Aditya Birla Sun Life ELSS Tax Saver FundAditya Birla Sun Life Mutual Fund | 13,49,941 | 1.93% | ₹262.3 Cr |
 SBI Flexicap FundSBI Mutual Fund | 11,28,993 | 0.99% | ₹219.4 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 8,84,772 | 0.93% | ₹171.9 Cr |
 Axis Small Cap FundAxis Mutual Fund | 8,72,885 | 0.55% | ₹169.6 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 6,40,910 | 1.36% | ₹124.5 Cr |
| Aditya Birla Sun Life Multi-Cap FundAditya Birla Sun Life Mutual Fund | 4,39,742 | 1.18% | ₹85.4 Cr |
| Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 3,93,680 | 1.25% | ₹76.5 Cr |
| Aditya Birla Sun Life Large & Mid Cap FundAditya Birla Sun Life Mutual Fund | 2,75,555 | 0.96% | ₹53.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 31 Oct 2025.Emcure Pharmaceuticals insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade
- Others: no market trade · 15 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Emcure Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Emcure Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Gland PharmaGLAND | 51,086 | 45.26 | 4.93 | +17.6% | +46.5% | 11.6% | 12.4% | 0.65% |
 IPCA LaboratoriesIPCALAB | 48,909 | 37.34 | 6.07 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Ajanta PharmaAJANTPHARM | 43,846 | 34.72 | 9.02 | +25.0% | +29.7% | 27.5% | 30.3% | 1.71% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 42,255 | 39.56 | 18.64 | +5.8% | +12.4% | 50.6% | 56.3% | 2.29% |
 Sai Life SciencesSAILIFE | 33,084 | 91.46 | 13.32 | – | – | 15.7% | 18.7% | 0.00% |
 Acutaas ChemicalsACUTAAS | 32,778 | 74.64 | 17.65 | +45.2% | +96.1% | 26.9% | 30.2% | 0.06% |
 Piramal PharmaPPLPHARMA | 31,807 | – | 3.91 | +9.4% | – | −2.6% | 2.3% | 0.00% |
 WockhardtWOCKPHARMA | 30,891 | 75.53 | 6.25 | +18.4% | – | 8.8% | 7.4% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Emcure Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹3.60 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 4 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹3.60 |
| 14 Aug 2025 | Final | ₹3.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Emcure Pharmaceuticals announcements
Oct 2026
14 Oct · Analysts
Sep 2026
23 Sep · General Updates
Emcure Pharmaceuticals share price by year
Each calendar year to 2025.Emcure Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,364.50 | −5.7% | 1,504.50 | 905.60 |
| 2024 | 1,447.10 | – | 1,526.60 | 1,236.70 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 10 Jul 2024.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 1,875.00 | 1,886.20 | 1,846.30 | 1,865.00 | 1,865.97 | 61,420 | 53.0% |
| 28 Oct 2026 | 1,875.70 | 1,889.20 | 1,839.90 | 1,875.00 | 1,861.42 | 62,133 | 59.5% |
| 27 Oct 2026 | 1,782.80 | 1,881.10 | 1,782.80 | 1,875.20 | 1,859.95 | 1,13,835 | 58.8% |
| 26 Oct 2026 | 1,773.20 | 1,794.30 | 1,751.00 | 1,780.20 | 1,770.76 | 1,38,616 | 58.7% |
| 23 Oct 2026 | 1,776.00 | 1,799.00 | 1,724.80 | 1,770.40 | 1,748.89 | 1,41,412 | 52.9% |
| 22 Oct 2026 | 1,746.00 | 1,811.10 | 1,716.00 | 1,782.60 | 1,770.87 | 1,13,203 | 53.4% |
| 21 Oct 2026 | 1,770.00 | 1,778.90 | 1,725.10 | 1,755.10 | 1,748.55 | 94,219 | 60.7% |
| 19 Oct 2026 | 1,801.00 | 1,829.00 | 1,746.50 | 1,766.60 | 1,789.51 | 1,08,214 | 54.5% |
| 16 Oct 2026 | 1,836.00 | 1,849.30 | 1,816.20 | 1,820.60 | 1,826.45 | 39,565 | 53.5% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- EMCURE
- BSE code
- 544210
- ISIN
- INE168P01015
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.emcure.com
- CIN
- L24231PN1981PLC024251
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1981
- Registered office
- Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune 411057, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, BSE MidCap, Nifty Total Market